Alfredo M. Lopez-Yunez
Research Subjects
Research Interests
Alfredo M. Lopez-Yunez has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Askiel Bruno
From the Department of Neurology, Indiana University School of Medicine, Indianapolis, Ind (A.M.L.-Y., A.B., L.S.W., E.Y., J.B.); Roudebush Veterans Administration Medical Center, Indianapolis, Ind (L.S.W.); Regenstrief Institute for Health Care (L.S.W.), Indianapolis, Ind; and Sanatorio Mitre, Buenos Aires, Argentina (Z.C.).
1 shared publicationCristina Zurrú
From the Department of Neurology, Indiana University School of Medicine, Indianapolis, Ind (A.M.L.-Y., A.B., L.S.W., E.Y., J.B.); Roudebush Veterans Administration Medical Center, Indianapolis, Ind (L.S.W.); Regenstrief Institute for Health Care (L.S.W.), Indianapolis, Ind; and Sanatorio Mitre, Buenos Aires, Argentina (Z.C.).
1 shared publicationEngin Yilmaz
From the Department of Neurology, Indiana University School of Medicine, Indianapolis, Ind (A.M.L.-Y., A.B., L.S.W., E.Y., J.B.); Roudebush Veterans Administration Medical Center, Indianapolis, Ind (L.S.W.); Regenstrief Institute for Health Care (L.S.W.), Indianapolis, Ind; and Sanatorio Mitre, Buenos Aires, Argentina (Z.C.).
1 shared publicationJ Biller
1 shared publication- Jake Yue Chen
Department of Biomedical Informatics and Data Science, School of Medicine, The University of Alabama at Birmingham (UAB), United States
1 shared publication José Biller
From the Department of Neurology, Indiana University School of Medicine, Indianapolis, Ind (A.M.L.-Y., A.B., L.S.W., E.Y., J.B.); Roudebush Veterans Administration Medical Center, Indianapolis, Ind (L.S.W.); Regenstrief Institute for Health Care (L.S.W.), Indianapolis, Ind; and Sanatorio Mitre, Buenos Aires, Argentina (Z.C.).
1 shared publication
Latest Publications
- Open Access
- 17 December 2012
- Published by Springer Nature in BMC Systems Biology
- Vol. 6 (S3) , S16
Genome-wide meta-analysis of genetic susceptible genes for Type 2 Diabetes
Background: Many genetic studies, including single gene studies and Genome-wide association studies (GWAS), aim to identify risk alleles for genetic diseases such as Type II Diabetes (T2D). However, in T2D studies, there is a significant amount of the hereditary risk that cannot be simply explained by individual risk genes. There is a need for developing systems biology approaches to integrate comprehensive genetic information and provide new insight on T2D biology. Methods: We performed comprehensive integrative analysis of Single Nucleotide Polymorphisms (SNP's) individually curated from T2D GWAS results and mapped them to T2D candidate risk genes. Using protein-protein interaction data, we constructed a T2D-specific molecular interaction network consisting of T2D genetic risk genes and their interacting gene partners. We then studied the relationship between these T2D genes and curated gene sets. Results: We determined that T2D candidate risk genes are concentrated in certain parts of the genome, specifically in chromosome 20. Using the T2D genetic network, we identified highly-interconnected network "hub" genes. By incorporating T2D GWAS results, T2D pathways, and T2D genes' functional category information, we further ranked T2D risk genes, T2D-related pathways, and T2D-related functional categories. We found that highly-interconnected T2D disease network “hub” genes most highly associated to T2D genetic risks to be PI3KR1, ESR1, and ENPP1. The well-characterized TCF7L2, contractor to our expectation, was not among the highest-ranked T2D gene list. Many interacted pathways play a role in T2D genetic risks, which includes insulin signalling pathway, type II diabetes pathway, maturity onset diabetes of the young, adipocytokine signalling pathway, and pathways in cancer. We also observed significant crosstalk among T2D gene subnetworks which include insulin secretion, regulation of insulin secretion, response to peptide hormone stimulus, response to insulin stimulus, peptide secretion, glucose homeostasis, and hormone transport. Overview maps involving T2D genes, gene sets, pathways, and their interactions are all reported. Conclusions: Large-scale systems biology meta-analyses of GWAS results can improve interpretations of genetic variations and genetic risk factors. T2D genetic risks can be attributable to the summative genetic effects of many genes involved in a broad range of signalling pathways and functional networks. The framework developed for T2D studies may serve as a guide for studying other complex diseases.
- 17 December 2012
- Published by Springer Nature in BMC Systems Biology
- Vol. 6 (S3) , S16
Open AccessGenome-wide meta-analysis of genetic susceptible genes for Type 2 Diabetes
Background: Many genetic studies, including single gene studies and Genome-wide association studies (GWAS), aim to identify risk alleles for genetic diseases such as Type II Diabetes (T2D). However, in T2D studies, there is a significant amount of the hereditary risk that cannot be simply explained by individual risk genes. There is a need for developing systems biology approaches to integrate comprehensive genetic information and provide new insight on T2D biology. Methods: We performed comprehensive integrative analysis of Single Nucleotide Polymorphisms (SNP's) individually curated from T2D GWAS results and mapped them to T2D candidate risk genes. Using protein-protein interaction data, we constructed a T2D-specific molecular interaction network consisting of T2D genetic risk genes and their interacting gene partners. We then studied the relationship between these T2D genes and curated gene sets. Results: We determined that T2D candidate risk genes are concentrated in certain parts of the genome, specifically in chromosome 20. Using the T2D genetic network, we identified highly-interconnected network "hub" genes. By incorporating T2D GWAS results, T2D pathways, and T2D genes' functional category information, we further ranked T2D risk genes, T2D-related pathways, and T2D-related functional categories. We found that highly-interconnected T2D disease network “hub” genes most highly associated to T2D genetic risks to be PI3KR1, ESR1, and ENPP1. The well-characterized TCF7L2, contractor to our expectation, was not among the highest-ranked T2D gene list. Many interacted pathways play a role in T2D genetic risks, which includes insulin signalling pathway, type II diabetes pathway, maturity onset diabetes of the young, adipocytokine signalling pathway, and pathways in cancer. We also observed significant crosstalk among T2D gene subnetworks which include insulin secretion, regulation of insulin secretion, response to peptide hormone stimulus, response to insulin stimulus, peptide secretion, glucose homeostasis, and hormone transport. Overview maps involving T2D genes, gene sets, pathways, and their interactions are all reported. Conclusions: Large-scale systems biology meta-analyses of GWAS results can improve interpretations of genetic variations and genetic risk factors. T2D genetic risks can be attributable to the summative genetic effects of many genes involved in a broad range of signalling pathways and functional networks. The framework developed for T2D studies may serve as a guide for studying other complex diseases.
- 1 January 2001
- Published by Wolters Kluwer Health in Stroke
- Vol. 32 (1) , 12-16
Protocol Violations in Community-Based rTPA Stroke Treatment Are Associated With Symptomatic Intracerebral Hemorrhage
Background —Recombinant tissue plasminogen activator (rTPA) is an established treatment for acute ischemic stroke. The rate and type of protocol violations in rTPA use and their effect on patient outcomes in this setting are not well understood. Objective —The objective of this study was to examine associations between protocol violations and outcomes in community-based rTPA use. Methods —We reviewed medical records of stroke patients treated with rTPA in 10 acute-care hospitals in Indianapolis from July 1996 to February 1998 and assessed complications and outcome. Retrospective National Institute of Health Stroke Scale (on admission and discharge), Canadian Neurological Scale, and length of hospital stay were calculated. Appropriate use of rTPA was determined by the National Institute of Neurological Disorders and Stroke (NINDS) protocol. Results —Fifty patients (mean age, 66 years; 76% white; 56% men) were treated by general neurologists (70%), stroke neurologists (24%), or emergency physicians (6%). Mean times to hospital arrival, brain CT, and start of rTPA infusion were 44, 86, and 141 minutes, respectively. In-hospital mortality rate was 10% (4 intracerebral hemorrhage [ICH], 1 cardiogenic shock). Complications were more frequent among patients with protocol violations (n=8) compared with those without all hemorrhages (75% versus 10%, P P P Conclusions —NINDS protocol violations are relatively common and are associated with symptomatic cerebral and systemic hemorrhages. When the NINDS protocol is strictly followed, hemorrhage rates in community-based rTPA use are similar to those in the NINDS trial.
- 1 January 2001
- Published by Wolters Kluwer Health in Stroke
- Vol. 32 (1) , 12-16
Protocol Violations in Community-Based rTPA Stroke Treatment Are Associated With Symptomatic Intracerebral Hemorrhage
Background —Recombinant tissue plasminogen activator (rTPA) is an established treatment for acute ischemic stroke. The rate and type of protocol violations in rTPA use and their effect on patient outcomes in this setting are not well understood. Objective —The objective of this study was to examine associations between protocol violations and outcomes in community-based rTPA use. Methods —We reviewed medical records of stroke patients treated with rTPA in 10 acute-care hospitals in Indianapolis from July 1996 to February 1998 and assessed complications and outcome. Retrospective National Institute of Health Stroke Scale (on admission and discharge), Canadian Neurological Scale, and length of hospital stay were calculated. Appropriate use of rTPA was determined by the National Institute of Neurological Disorders and Stroke (NINDS) protocol. Results —Fifty patients (mean age, 66 years; 76% white; 56% men) were treated by general neurologists (70%), stroke neurologists (24%), or emergency physicians (6%). Mean times to hospital arrival, brain CT, and start of rTPA infusion were 44, 86, and 141 minutes, respectively. In-hospital mortality rate was 10% (4 intracerebral hemorrhage [ICH], 1 cardiogenic shock). Complications were more frequent among patients with protocol violations (n=8) compared with those without all hemorrhages (75% versus 10%, P P P Conclusions —NINDS protocol violations are relatively common and are associated with symptomatic cerebral and systemic hemorrhages. When the NINDS protocol is strictly followed, hemorrhage rates in community-based rTPA use are similar to those in the NINDS trial.
- 1 January 1999
- p. 11-6
Glenn Gould: insights into the cause of death of the great pianist.